Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More

Author: Lara Goldstein | April 24, 2023 03:57pm

LSD Trial Study Shows Potential For Major Depression

• Psychedelics biopharma company Mind Medicine Inc. (NASDAQ:MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a treatment of Major Depressive Disorder (MDD).
• The double-blind Phase 2 study demonstrated “significant, rapid, durable and beneficial effects” on the mitigation of MDD symptoms. Read more HERE.

Canada's Large Scale Psilocybin Macrodose Trial

• Canadian biopharma company Apex Labs Ltd., has received Health Canada’s approval for a comprehensive, “statistically powered” macro-and-multi dose advanced psilocybin trial on 160 patients. 
• The trial’s primary indication (severe depression within PTSD) is accompanied by secondary indications, including chronic pain and anxiety. Read more HERE.

Study Details How One Firm Approaches Autism

The partnership between KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC:NMLSF) has begun recruiting participants. This is believed to be the first-ever clinical trial assessing the effects of psilocybin in adults diagnosed with Fragile X Syndrome (FXS), the leading genetic cause of autism.

The study will take place at KGK’s London facility in Ontario, Canada. It will test the safety and efficacy of repetitive oral microdoses (1.5 milligrams) of Nova’s synthetic psilocybin NM-1001 on the cognitive and behavioral symptoms commonly seen in people with FXS diagnosis. Read more HERE.

Novel Compound A Potential Treatment Of MS

FSD Pharma Inc. (NASDAQ:HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targeting multiple sclerosis.

The study is set to evaluate safety and tolerability of orally-administered Lucid-MS,  which has been shown to prevent and reverse myelin degradation. Read more HERE.

The Milestone Round

• Awakn Life Sciences (OTC:AWKNF) has an upcoming Phase 3 ketamine clinical trial for patients with severe AUD.

• Australia’s Monash University will test PharmAla’s MDMA in a clinical trial.

• Clearmind (NASDAQ:CMND) has engaged a contract research organization for its upcoming first-in-human study of MEAI compound while also filing an additional provisional patent application with partner SciSparc (NASDAQ:SPRC). 

• Three studies have assessed the use of psychedelic-assisted therapy for teenagers, older adults, and borderline disorder patients with auspicious findings.

• Silo Pharma (NASDAQ:SILO) and Bright Minds (NASDAQ:DRUG) are working on novel psychedelic-inspired meds for the treatment of stress, anxiety, PTSD and depression.

• Lobe Sciences (OTC:LOBEF) agreed to acquire a SCD treatment.

• Real estate company Healing CREI is partnering with SaaS platform Heally Inc.

• Red Light Holland (OTC:TRUFF) updated on its manufacturing plans for homogenized natural psilocybin microdosing capsules.

• Find out the latest on states’ reform bills and the yet uncertain future of ketamine telehealth clinics following a backlash to DEA’s new proposed regulations.

• Numinus Wellness (OTC:NUMIF) CEO Payton Nyquvest discussed the company’s quarterly financials and latest launched offers.

• Check out BZ’s interview series discussing decolonization in the psychedelics space and Musk’s call on a “fictional opioid”.

See Also: Last Week's Edition Of 'Psyched'

Psychedelics ETF Weekly Performance April 17-21:

AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, April 24 at $1.82. That's down slightly from April 17, when it opened at $1.85. It reached a weekly high of $1.88 on Wed., April 19. For this ETF, the yearly price range is set between $4.35 and $1.70.

Benzinga’s Psychedelics Capital Conference 2023

Missed our Psychedelics Capital Conference? Here's some EXCLUSIVE coverage from the event’s second edition:

• Johns Hopkins Professor: Psychedelic Medicine Could Get Messy, Calls For 'Right, Smart, Non-Restrictive, Yet Preventive' Regulations

• Investing In The Unique Growth Market Of Psychedelics

• MDMA Therapy Experts Debate Upcoming Approval, Psychedelic Market Opps

• Ketamine Therapy Leaders Share Bold Vision For Future Of Psychedelics

• In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'

• Fireside With Enveric Biosciences's Dr. Tucker, Unlocking Psychedelic Healing Benefits

• Making The World A Better Place, How Psychedelics Are Helping

Posted In: AWKNF CMND DRUG HUGE LOBEF MNMD NMLSF NUMIF PSIL SILO SPRC TRUFF